oxazoles has been researched along with vorinostat in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Auzzas, L; Giannini, G; Hanessian, S; Marzi, M; Vinci, V | 1 |
| Chen, Y; Du, Y; Li, S; Lin, Q; Ma, YY; Mo, H; Wang, Y; Zhang, K; Zhang, R; Zhao, DG; Zou, W | 1 |
| Alcitepe, İ; Karatekin, İ; Kaymaz, BT; Salcin, H | 1 |
3 other study(ies) available for oxazoles and vorinostat
| Article | Year |
|---|---|
Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
Topics: Alkynes; Cyclobutanes; Drug Design; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Hydroxyurea; Molecular Structure; Oxazoles; Vorinostat; Zinc | 2006 |
Synthesis and anticancer activity of novel histone deacetylase inhibitors that inhibit autophagy and induce apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Oxazoles; Vorinostat | 2022 |
HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Oxazoles; Pyridines; Pyrroles; Vorinostat | 2022 |